Clinical Trial Update: BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the optimal duration of BP-C1 monotherapy in patients with metastatic breast cancer (Stage IV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BP-C1

Snippet

Sponsor: Meabco A/S | Conditions: Metastatic Breast Cancer, Stage IV Breast Cancer | Phase 2 | Status: COMPLETED